IL18 and inflammatory bowel disease: By inhibiting autophagy and inducing mitochondrial ROS, TMAO activates NLRP3 inflammasome, leading to the release and pyroptosis of IL-1β/IL-18 dependent on caspase-1 in colon epithelium, which is a hallmark of IBD severity.